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ABSTRACT
With the continued transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) throughout
the world, identification of highly suspected COVID-19 patients remains an urgent priority. In this study, we
developed and validated COVID-19 risk scores to identify patients with COVID-19. In this study, for patient-wise
analysis, three signatures, including the risk score using radiomic features only, the risk score using clinical
factors only, and the risk score combining radiomic features and clinical variables, show an excellent
performance in differentiating COVID-19 from other viral-induced pneumonias in the validation set. For lesionwise analysis, the risk score using three radiomic features only also achieved an excellent AUC value. In
contrast, the performance of 130 radiologists based on the chest CT images alone without the clinical
characteristics included was moderate as compared to the risk scores developed. The risk scores depicting the
correlation of CT radiomics and clinical factors with COVID-19 could be used to accurately identify patients with
COVID-19, which would have clinically translatable diagnostic and therapeutic implications from a precision
medicine perspective.
www.aging-us.com
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INTRODUCTION
The novel severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) has been identified as the cause of
coronavirus disease 2019 (COVID-19) in Wuhan, Hubei
Province, China in late 2019 [1]. It spread rapidly,
resulting in a global pandemic, with over 23,342,798
confirmed cases and 807,383 deaths globally as of
August 2020 [2]. COVID-19 developed through personto-person spread of SARS-CoV-2 via respiratory droplets
is associated with adverse outcomes, and increased
short- and long-term morbidity and mortality [1]. The
identification of suspected patients with COVID-19 is
urgently needed so that we can evaluate patients at greater
risk and/or more vulnerable to COVID-19 and facilitate
appropriate clinical decision making for earlier quarantine
and interventions that could minimize the severity of
COVID-19, thus substantially improving patient outcome.
Currently, the standard for the diagnosis of COVID-19 is
the use of the reverse transcription polymerase chain
reaction (RT-PCR) to detect SARS-CoV-2 in lower
throat respiratory tract secretions, sputum, swabs, or
blood samples [3]. However, the sensitivity of the RTPCR varies within a range of 60–71% because its
accuracy could be compromised by the quality of the
RT-PCR kit, the varying lowest limit of detection (LOD)
of virus RNA copies per mL with the kits of different
vendors, the quality and location of specimens collected
(upper vs. lower respiratory tract), the low viral load in
test specimens collected, and/or sampling timing
(different phases of the disease), thus easily leading to
false negative results [3, 4].
Recently, the European Society for Radiotherapy and
Oncology (ESTRO) and the American Society for
Radiation Oncology (ASTRO) jointly issued an
ESTRO-ASTRO consensus statement to recommend
the use of simulation-CT in clinical practice as a
COVID-19 screening tool during the SARS-CoV-2
pandemic [5]. The consensus statement suggests that the
CT imaging techniques used in radiotherapy are a
potential screening opportunity and may be an added
value to identify asymptomatic COVID-19 patients that
are not identified by standard screening in hospitals
(e.g., temperature screening and questions regarding
COVID-19-related symptoms) [5]. The consensus was
based on the fact that studies using CT imaging have
identified patients with COVID-19 with negative RTPCR results [6, 7]. In particular, thoracic CT screening
allows early diagnosis of COVID-19, when patients are
still in the asymptomatic phase [5–8].

as use to assess disease extent and follow-up [4]. The
principal CT manifestations include ground-glass
opacification (GGO) with or without consolidative
abnormalities and a bilateral, peripheral, and diffuse
distribution with or without an involvement of the lower
lobes [4, 9]. Especially, asymptomatic patients with
initially negative RT-PCR results also showed early CT
changes [9].
However, the identification of CT manifestations highly
relies on radiologists’ clinical experience due to the
qualitative CT features used, which might pose a
challenge to resource-limited clinics with health care
disparities for COVID-19 diagnosis. Meanwhile, COVID19 shares similar manifestations with severe acute
respiratory syndrome (SARS), Middle East respiratory
syndrome (MERS), and other viral pneumonias in the
images of qualitative CT, thus significantly reducing the
specificity of qualitative CT for COVID-19 detection
[10]. As such, chest CT may be helpful in making the
diagnosis, but no finding can completely confirm or
exclude the possibility of COVID-19 without including
other clinical characteristics due to the extremely low
specificity of 25% of the chest CT alone for diagnostic
purposes [4]. These aspects of qualitative CT emphasize
limitations of the current imaging model for diagnosing
COVID-19 before the occurrence of its clinical symptoms
and have compelled radiologists to call for new, imagingbased methods to answer this critical clinical question.
Digital biopsy techniques have evolved to use highthroughput processes to extract quantifiable radiomic
features from medical images and have the potential to
facilitate disease characterization and assessment. The
aim of this study was to develop and validate clinically
translatable COVID-19 risk scores encompassing chest
CT radiomics with or without clinical characteristics
included for distinguishing COVID-19 from other viral
pneumonia. As a reference, we also compared the
prediction performance of the risk scores with that of 130
well-experienced radiologists from the epicenters of
COVID-19 outbreak and non-epicenters in China as
well as that of other machine learning methods in this
study. The risk scores integrating the spatial information
derived from chest CT radiomic features and/or clinical
characteristics could better characterize the SARS-CoV-2
infection landscape, which still significantly overlaps
with other virus-induced pneumonias in visual inspection
of CT manifestations.

RESULTS
Patient characteristics

Chest radiography and CT imaging have a sensitivity of
56–98% to identify suspected patients before the
occurrence of positive RT-PCR detection results as well

www.aging-us.com
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The clinical characteristics of patient data used are shown
in Table 1. The COVID-19 patients had significantly
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Table 1. Clinical characteristics of the COVID-19 and non-COVID-19 (viral-induced pneumonias) patient cohorts.
Characteristics
Age, years
>50
≤50
Lesion number
1≤n<3
3≤n<5
5 ≤ n < 10
10 ≤ n
Sex
Male
Female
Epidemiologic contact
Travel history to Hubei Province, Chinaξ
Travel history to Wenzhou city, Zhejiang
Province, Chinaξ
Unknown exposure
Symptoms
Fever
Dyspnea
Chest tightness
Cough
Sputum
Rhinorrhea
Asymptomatic
Laboratory results
D-dimers, mg/L
C-reactive protein, mg/L
White blood cells, 109/L
Creatine kinase isoenzyme, µg/L
Lactate dehydrogenase, U/L
CT manifestations
Location
Unilateral
Bilateral
Distribution
Central
Peripheral
Central + peripheral
Main features
Ground-glass opacity
Consolidation
Linear opacity
Mixed type
Interstitial change
Septal thickening
Fine reticular opacity
Other features
Vascular thickening
Crazy-paving pattern
Pleural thickening
Pleural effusion

COVID-19
patients (n = 108)

Non-COVID-19 patients (viralinduced pneumonias) (n = 77)

P-value

41
67

27
50

0.002
0.234

14
12
64
18

72
5
0
0

<0.001
0.729
<0.001
<0.001

44
64

28
49

0.322
0.876

12

—

—

22

—

—

74

—

—

89
51
17
67
23
37
17*

57
55
14
75
54
65
2

0.437
0.051
0.121
0.532
0.067
0.213
—

0.51 ± 0.44
12.32 ± 18.7
3.31 ± 2.13
9.12 ± 5.56
245.91 ± 75.35

0.52 ± 0.34
7.49 ± 14.27
3.58 ± 1.94
13.93 ± 5.69
167.35 ± 42.88

0.897
0.055
0.112
<0.001
<0.001

1
107

75
2

<0.001
<0.001

1
73
34

3
72
2

0.233
0.191
0.013

67
11
23
7

43
9
12
13

0.278
0.055
0.231
0.101

37
11

25
39

0.062
0.012

17
45
13
0

39
39
2
0

0.054
0.123
0.053
—

ξ

Two epicenters of the COVID-19 outbreak in China.
*These were tested as close contacts with confirmed COVID-19 patients.
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higher lesion numbers, CK-MB activity, LDH activity,
and bilateral, peripheral, or mixed central and peripheral
pulmonary distribution than the non-COVID-19 viralinduced pneumonia patients. Most of the symptoms,
laboratory results, and CT manifestations had no
significant differences between COVID-19 and nonCOVID-19 patients (Table 1). Representative images of
COVID-19 pneumonia, adenovirus pneumonia, cytomegalovirus pneumonia, and influenza virus pneumonia
are shown in Figure 1.
Human diagnosis of COVID-19
Supplementary Figure 5 shows the geographic
distribution of 130 radiologists from 10 provinces in
China, including Hubei. The performance of the
130 radiologists based on the chest CT images only
(without providing patients’ clinical information and
laboratory results) was moderate due to the overlap
of CT manifestations between COVID-19 lesions and

non-COVID-19 viral pneumonia lesions using a
supervised human learning format (Table 2). Notably,
the radiologists from Hubei Province, China, the
epicenter of the COVID-19 outbreak in China, had a
better performance than the radiologists from outside of
Hubei Province (P < 0.05).
Patient-based risk scores
The patient-based risk scores using radiomic features
only, clinical factors only, and a combination of
radiomic features and clinical factors are shown in
Figure 2A–2C and Equations (2)–(4), respectively. The
utility of the risk scores achieved area under the receiver
operating characteristic curve (AUC) values of 0.791
(95% confidence interval [CI]: 0651–0.932), 0.813
(95% CI: 0.682–0.944), and 0.915 (95% CI: 0.841–
0.991), respectively, in the validation set (Table 3 and
Figure 3), suggesting a high performance of COVID-19
classification using the COVID-19 risk scores.

Figure 1. Representative images of COVID-19 pneumonia, adenovirus pneumonia, cytomegalovirus pneumonia, and
influenza virus pneumonia. (A) A transverse CT image from a 35-year-old man with adenovirus pneumonia showing bilateral ground-glass
opacities in the upper lobes with a rounded morphology (arrows). (B) COVID-19: A transverse CT image from a 57-year-old man with COVID19 showing more limited ground-glass opacities in the bilateral upper lobes with an elliptical morphology (arrows). (C) A transverse CT image
obtained in a 45-year-old female with cytomegalovirus pneumonia showing bilateral ground-glass and burr-like, denser, and less transparent
distribution (arrows). (D) A transverse CT image of a 61-year-old man diagnosed with influenza virus pneumonia showing bilateral groundglass opacities in the upper lobes (arrows).
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Table 2. Performance of the radiologists to diagnose COVID-19 from chest CT images.
Performance

Assistant
attending
radiologists

Associate
attending
radiologists

Attending
radiologists

Overall

*

n
Average time for reviewing each CT
image (sec)
Precision
Recall
Specificity
F1
Accuracy
n
Average time for reviewing each CT
image (sec)
Precision
Recall
Specificity
F1
Accuracy
n
Average time for reviewing each CT
image (sec)
Precision
Recall
Specificity
F1
Accuracy
Average time for reviewing each CT
image (sec)
Precision
Recall
Specificity
F1
Accuracy

Radiologists from
Hubei Province,
China* (n = 40)
13

Radiologists from outside
of Hubei Province, China
(n = 90)
42

3.2 ± 2.3

3.3 ± 2.1

0.132

0.49
0.30
0.57
0.37
0.41
15

0.3
0.23
0.39
0.28
0.30
34

0.153
0.121
0.058
0.131
0.154
—

3.3 ± 2.6

3.6 ± 2.8

0.053

0.49
0.29
0.57
0.37
0.41
12

0.35
0.24
0.39
0.28
0.30
14

0.002
0.042
0.051
0.032
0.021
—

3.1 ± 2.4

3.2 ± 2.9

0.129

0.47
0.29
0.54
0.35
0.39

0.34
0.22
0.40
0.26
0.29

0.215
0.055
0.067
0.042
0.102

3.2 ± 0.1

3.4 ± 0.2

0.054

0.48
0.29
0.56
0.36
0.41

0.35
0.23
0.39
0.28
0.30

<0.001
0.027
0.002
0.034
0.029

P-value
—

Hubei Province was the epicenter of the COVID-19 outbreak in China.

The patient − based risk score using radiomic features only
= −3.785 + 19.563  GLRLM_LRLGE_(25,90) (2)
+ 0.002  ID_Global_Max

The patient − based risk score using clinical factors only
= −15.680 + 2.833  lesion number + 0.104
 lactate dehydrogenase − 1.674

(3)

 creatine kinase isoenzymes
The patient − based risk score combining radiomics
and clinical features
= −114.053 + 9.911  lesion number + 122.045
 GLRLM_LRLGE_(25,90) + 0.0196

(4)

 ID_Global_Max + 0.334
 lactate dehydrogenase − 7.593
 creatine kinase isoenzymes

www.aging-us.com
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where GLRLM_LRLGE_(25, 90) represents the
radiomic feature, long-run, low gray-level emphasis,
which describes the distribution of the long
homogeneous runs with low gray-levels within the
image. The numbers in the brackets represent the
parameters used to calculate that particular radiomic
feature. ID_Global_max represents the radiomic feature
intensity direct global max, which describes that the
binary mask was preprocessed for the features derived
directly from the image intensity. A detailed description
of the parameters used is shown in Figure 2.
In contrast, the developed patient-based random forest
models demonstrate comparable AUC values, precision,
recall, specificity, F1, and accuracy as compared to the
patient-based risk scores in the validation set (Table 3).
The results of the decision curve analysis (DCA) to
evaluate the clinical utility of the risk scores and the

AGING

Figure 2. The patient-based COVID-19 risk scores demonstrated by nomograms. (A) The risk score using radiomic features only. (B)
The risk score using clinical factors only. (C) The risk score combining radiomic features and clinical factors. GLRLM_LRLGE_(25, 90) represents
the radiomic feature long run low gray-level emphasis, which describes the distribution of the long homogeneous runs with low gray-levels
within the image. The numbers in the bracket represents the parameters used to calculate that particular radiomic feature. The parameters
of 25 and 90 in GLRLM_LRLGE represent the binary mask in 2.5D and 90 degrees, which describes that the GLRLM was computed in 2D slice
by slice; then, the occurrence of run length from 90 degrees from all 2D image slices was summed. ID_Global_max represents the radiomic
feature intensity direct global max, which describes that the binary mask was preprocessed for the features derived directly from the image
intensity. The binary mask in ID_Global_max can be modified through intensity thresholding, by binary erosion, and using only the binary
slice with the maximum area. The unit for lactate dehydrogenase is U/L. The unit for creatine kinase isoenzymes is µg/L. Supplementary
Appendix 2 explains how to use the nomograms.
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Table 3. The classification performance using patient-based COVID-19 risk scores and random forest models.
Signature

AUC

Precision

Recall

Specificity

F1 score

Accuracy

COVID-19 risk score using
radiomic features only

0.807
(0.717–0.853)

0.823
(0.703–855)

0.792
(0.711–0.834)

0.843.
(0.781–0.867)

0.807
(0.723–0.897)

0.811
(0.703–0.966)

COVID-19 risk score using
clinical variables only

0.882
(0.847–0.921)

0.877
(0.712–0.903)

0.897
(0.784–0.922)

0.901
(0.879–0.944)

0.887
(0.813–0.922)

0.892
(0.824–0.927)

COVID-19 risk score using
combined radiomic and clinical
variables

0.935
(0.913–0.978)

0.902
(0.878–0.966)

0.942
(0.807–0.989)

0.921
(0.893–0,964)

0.899
(0.812–0.962)

0.923
(0.879–0.978)

Random forest using radiomic
features only

0.837
(0.775–0.901)

0.712
(0.645–0,834)

0.896
(0.812–0.934)

0.877
(0.812–0.921)

0.793
(0.743–0.854)

0.845
(0.798–0.939)

Random forest using clinical
variables only

0.925
(0.892–0.963)

0.867
(0.772–0.934)

0.914
(0.854–0.963)

0.937
(0.879–0.987)

0.890
(0.807–0.919)

0.955
(0.913–0.977)

Random forest using radiomic
and clinical variables

0.958
(0.911–0.989)

0.886
(0.719–0.968)

0.934
(0.812–0.977)

0.954
(0.903–0.987)

0.909
(0.855–0.950)

0.966
(0.923–0.989)

COVID-19 risk score using
radiomic features only

0.791
(0.651–0.932)

0.804
(0.723–0.,902)

0.733
(0.693–0.854)

0.822
(0.734–0.876)

0.767
(0.717–0.856)

0.797
(0.701–0.892)

COVID-19 risk score using
clinical variables only

0.813
(0.682–0.944)

0.821
(0.721–0.876)

0.934
(0.877–0.965)

0.917
(0.832–0.989)

0.874
(0.793–0.941)

0.882
(0.769–0.923)

COVID-19 risk score using
combined radiomic and clinical
variables

0.915
(0.841–0.991)

0.855
(0.744–0.913)

0.945
(0.897–0.988)

0.934
(0.899–0.989)

0.898
(0.844–0.953)

0.919
(0.87–0.955)

Random forest using radiomic
features only

0.872
(0.771–0.973)

0.809
(0.723–0.881)

0.913
(0.856–0.956)

0.896
(0.859–0.931)

0.858
(0.739–0.907)

0.868
(0.792–0.899)

Random forest using clinical
variables only

0.949
(0.894–0.956)

0.902
(0.843–0.977)

0.965
(0.913–0.998)

0.967
(0.943–0.997)

0.932
(0.899–0.956)

0.956
(0.933–0.979)

Random forest using radiomic
and clinical variables

0.979
(0.949–0.997)

0.943
(0.879–0.987)

0.987
(0.897–0.999)

0.934
(0.917–0.986)

0.964
(0.889–0.981)

0.963
(0.892–0.992)

Delong test for
AUC values

Training set

Z = 7.241,
P = 0.000

Z = 8.574,
P = 0.000

Validation set

Z = 9.307,
P = 0.000

Z = 7.896,
P = 0.000

The values in the brackets represent the 95% confidence interval.
Abbreviations: AUC, area under the ROC curve.

random forest models built in this study are shown
in Figure 3E, 3F. The risk scores show a comparable
clinical utility as compared to the random forest
models.
Lesion-wise COVID-19 risk score with radiomic
features only
To characterize different infectious lesions within the
same patient, a lesion-based risk score using three
radiomic features alone was also constructed (Figure 4
and Equation (5)). The utility of the risk score achieved
an AUC value of 0.931 (95% CI: 0.898–0.956) (Table 4
and Figure 5A).

In contrast, the lesion-based weighted support vector
machine (WSVM) model using the radiomic features
only demonstrates a comparable AUC value, precision,
recall, specificity, F1, and accuracy as compared to the
lesion-based risk score (Table 4). The results of the
DCA analysis to evaluate the clinical utility of the risk

The lesion
− based risk score using radiomics features alone
= −55.389 − 6.769  GLCM_Correlation _(25, 0,1)

(5)

+0.33  ID_Local_Range_Std + 0.136
GOH_Percentile _(15)

www.aging-us.com

where GLRLM_Correlation_(25,0,1) represents the
radiomic feature gray-level co-occurrence matrix with
statistical measurement of correlation between a pixel
and its neighbor over the whole image. The numbers in
the brackets represent the parameters used to calculate
that particular radiomic feature. ID_Local_Range_Std
represents the radiomic feature of intensity direct in the
neighborhood region, which describes the standard
deviation among all the voxels. GOH_Percentile_(15)
represents the radiomic feature gradient orient histogram,
which describes the percentiles of the occurrence
probability values in the histogram of the image. A
detailed description of the parameters used is shown in
Figure 4.
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Figure 3. The receiver operating characteristic (ROC) curves and the decision curve analysis (DCA) for the patient-based risk
scores and random forest models. (A) ROC curve for patient-based risk scores in the training set. (B) ROC curve for patient-based risk
scores in the validation set. (C) ROC curve for patient-based random forest models in the training set. (D) ROC curve for patient-based
random forest models in the validation set. (E) DCA for patient-based risk scores in the validation set. (F) DCA for patient-based random
forest models in the validation set. In (E) and (F), the x-axis of the decision curve is the threshold of the predicted probability using the risk
score to classify COVID-19 and non-COVID-19 patients. The y-axis shows the clinical decision net benefit for patients based on the
classification result in this threshold. The decision curves of the treat-all scheme (the monotonically decreasing dash-line curve in the figure)
and the treat-none scheme (the line when x equals zero) are used as references in the DCA. In this study, the treat-all scheme assumes that
all the patients had COVID-19; the treat-none scheme assumes that none of the patients had COVID-19. Abbreviations: AUC, area under the
ROC curve; 95% CI, 95% confidence interval.
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score and the WSVM model using radiomic features
only are shown in Figure 5B.

DISCUSSION
During the incubation period of SARS-CoV-2, before
the onset of clinical symptoms confirmed by positive
nucleic acid detection, about 96% of patients would
have non-specific CT imaging changes similar to other
viral pneumonias in the lungs, i.e., GGO, patchy
consolidation, and sub-solidification [4, 9, 11, 12]. In
this study, the performance of the radiomics-based risk
scores was compared to that of human diagnosis in
differentiating COVID-19 from viral pneumonia. We
demonstrated that both the patient-based risk score
using radiomic features only and the lesion-based risk
score using radiomic features only have significantly
better classification abilities than the human diagnosis
at the patient- and lesion-wise levels. This can partially
be attributed because without the aid of other clinical
information, radiologists might achieve a relatively low
sensitivity and specificity in differentiating COVID-19
from viral pneumonias based only on the chest CT
manifestations.
The risk score could provide a quantitative measure to
appropriately adjust the cut-off value based on desired
levels of recall and specificity to reduce the adverse
consequences of false negatives in the differentiation
of COVID-19. In addition, with the quantitative

measurements used, it might be useful to longitudinally
monitor disease progress over time or recurrence in the
recovered COVID-19 patients using delta radiomics
methods, although this possibility is still under
investigation.
In the patient-based COVID-19 risk scores, three
clinical variables, i.e., lesion number, LDH activity, and
CK-MB activity, show discriminative abilities for
COVID-19 detection. Notably, the imaging pattern
showing a multifocal appearance with a lesion number
larger than 3–5 could be used as a rapid cut-off in the
case of a strong suspicion of SARS-CoV-2 infection.
Meanwhile, LDH serves as an inflammatory predictor
in many pulmonary diseases, such as obstructive
disease, microbial pulmonary disease, and interstitial
pulmonary disease [13, 14]. A recent study showed that
refractory COVID-19 patients had increased blood LDH
and CRP levels. Moreover, another study demonstrated
that COVID-19 patients treated in the ICU had higher
levels of LDH and CRP than those not treated in the
ICU [15]. These observations suggest that LDH levels
might reflect the acute severe systemic inflammatory
response involved in cell-mediated immunity and
cytokine storms caused by SARS-CoV-2 infection,
which is a distinguishable biochemical parameter for
inflammation in the risk score.
Furthermore, a previous study suggested that the
increases in LDH and CK-MB levels were correlated

Figure 4. The lesion-based risk score using three radiomic features only. GOH_Percentile_(15) represents the radiomic feature
gradient orient histogram, which describes the percentiles of the occurrence probability values in the histogram of the image. The numbers in
the brackets represent the parameters used to calculate that particular radiomic feature. The parameter of 15 in GOH_Percentile represents
the histogram percentile. GLCM_Correlation_(25,0,1) represents the radiomic feature gray-level co-occurrence matrix with statistical
measurement of correlation between a pixel and its neighbor over the whole image, which describes that the gray-level co-occurrence matrix
was computed from the image inside the binary mask in 2.5D with the direction of the angle of intensity pair at 0 degrees and the distance
between the intensity pairs at 1. ID-Local_Range_Std represents the intensity direct in the neighborhood region, which describes the
standard deviation among all the voxels.
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Table 4. The diagnosis performance using the lesion-based risk score and weighted support vector machine.
AUC

Precision

Recall

Specificity

F1 score

Accuracy

Delong test
for AUC

0.931
(0.898–0.956)
0.949
(0.925–0.971)

0.976
(0.944–0.996)
0.969
(0.923–0.981)

0.891
(0.831–0.927)
0.904
(0.824–0.936)

0.921
(0.872–0.965)
0.942
(0.899–0.966)

0.927
(0.901–0.966)
0.935
(0.876–0.964)

0.902
(0.834–0.981)
0.987
(0.886–0.995)

Z = 4.371,
P < 0.000

Signature
COVID-19 risk
score
Weighted support
vector machine

The values in the brackets represent the 95% confidence interval (95% CI).
Abbreviations: AUC, area under the curve.

with SARS-CoV-2 mRNA levels in RT-PCR positive
patients [16]. As such, all three clinical variables in the
risk scores might emphasize the underlying biological
mechanism(s) related to COVID-19. The immunological
mechanism of SARS-CoV-2 infection still requires
further investigation.

coarse texture and regional heterogeneity as compared to
fine texture [17]. Therefore, GLRLM_LRLGE might be
associated with the coarseness of COVID-19 [18].
Consequently, a higher GLRLM_LRLGE, i.e., a coarser
texture on chest CT images, may be associated with a
higher risk of occurrence of COVID-19 [19].

In the patient-based COVID-19 risk scores, two radiomic
features, GLRLM_LRLGE_(25,90) and ID_Global_max,
were selected to build the risk score with significantly
strong discriminative abilities for COVID-19 detection
(i.e., the features with P < 0.001 in the multivariable
logistic regression). GLRLM_LRLGE had a higher
weight (larger coefficient) in the risk score compared to
other radiomics and clinical features. GLRLM_LRLGE
analyzes the spatial information within chest CT image
runs in the upper right quadrant of the GLRLM with long
run lengths and low gray-levels. The longer runs with
different gray-level intensities are closely linked with

Interestingly, three different radiomic features, GOH_
Percentile_(15), GLCM_Correlation_(25,0,1), and ID_
Local_Range_Std, were identified in our lesion-based
analysis. In particular, previous studies suggested that a
GLCM_correlation value might be inversely related with
the levels of vascular endothelial growth factor (VEGF),
which controls critical physiological functions in the lung
[20–22]. For example, a decrease in VEGF expression is
believed to be associated with acute lung injury and
alkaloid monocrotaline-pulmonary hypertension [23],
which is one of the most common comorbidities in
COVID-19 [24]. However, the relationship between

Figure 5. The receiver operating characteristic (ROC) curves and the decision curve analysis (DCA) for the lesion-based risk
score and weighted support vector machine model using radiomic features alone. (A) ROC curve. (B) DCA analysis. In (B), the xaxis of the decision curve is the threshold of the predicted probability using the risk score to classify COVID-19 and non-COVID-19 patients.
The y-axis shows the clinical decision net benefit for patients based on the classification result in this threshold. The decision curves of the
treat-all scheme (the monotonically decreasing dash-line curve in the figure) and the treat-none scheme (the line when x equals zero) are
used as references in the DCA. In this study, the treat-all scheme assumes that all patients had COVID-19; the treat-none scheme assumes
that none of the patients had COVID-19. Abbreviations: AUC, area under the curve; 95% CI, 95% confidence interval.
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radiomic features and the phenotypes linked to COVID19 is not well understood at present.
There are different processing methods for patientbased analysis. Some studies selected the largest lesion
and/or the most metabolically active lesion as a
representative lesion for that patient based on a method
reported previously [25, 26]. However, the large
heterogeneous lesions (often necrotic and/or with
multiple uptake peaks) may underestimate image
texture measurements [27]. Nevertheless, all the lesions
could be used for radiomics analysis, which enriches the
analysis through the use of the information derived from
all lesions. However, the method of averaging the
radiomic values of all lesions as the characteristic value
for one particular radiomic feature could dilute the
feature value of large lesions by other small lesions. As
such, in this study, a weighted power mean method was
used in the patient-based analysis to emphasize that the
lesions with relatively large volume represent the main
characteristics of the biological behavior and
characteristics of the disease type, while still retaining
the other small lesions representing a certain kind
of disease progression. In contrast, the lesion-based
analysis allowed us to examine each individual lesion
with a consideration of different infectious lesions
within the same patient.

Province, China, and might not fully represent the
spectrum of COVID-19 phenotypes. The relationships
between radiomic features and their underlying immune
interactions and biological mechanism(s) directing
COVID-19 progression at the early stage of SARS-CoV2 infection also remain to be explored. Third, although
the radiomic features and clinical variables associated
with disease progression were not evaluated in this study,
the findings of this research may still provide useful
insights for future studies to identify the underlying
mechanism(s) and relevant radiomic features for disease
severity, prognosis, and patient outcome of SARS-CoV-2
infection.

CONCLUSIONS
The point-of-care COVID-19 risk scores could be an
easy-to-use tool to quantitatively differentiate COVID-19
from other viral pneumonias. The risk scores using chest
CT radiomic features and/or clinical characteristics could
better characterize the SARS-CoV-2 infection landscape,
which still significantly overlaps with other virus-induced
pneumonias in visual inspection of CT manifestations.
The risk scores developed could potentially afford a
clinically translatable means to improve the diagnostic
confidence using chest CT for COVID-19 detection in
the future.

There could be certain bias introduced in the boundary
and volume contoured in the manual delineating process
by different radiologists, which could certainly affect the
radiomics values calculated. However, this kind of interobserver variation mainly influences the shape-related
radiomic features. It has relatively limited influence on
the features of GLRLM_LRLGE_(25, 90), ID_Global_
Max, GOH_Percentile_(15), GLCM_Correlation_(25,0,1),
and ID_Local_range_std selected in this study. A
previous study conducted by eight research centers in the
United States and one medical imaging center in Canada
suggested that the segmentation mainly affects the global
shape descriptors features, but has relatively little effect
on the texture and intensity features of the entire threedimensional volume [28]. Also, GLRLM_LRLGE_(25,
90), ID_Global_Max GOH_Percentile_(15), GLCM_
Correlation_(25,0,1), and ID_Local_range_std are
five important features in the texture and intensity
features category. A verification study is described in
Supplementary Appendix 3.

MATERIALS AND METHODS

As a retrospective study, this study has several
limitations. First, the patient cohort in this study is
relatively small. The use of digital biopsy technologies
with promising retrospective radiomics analyses
must still be further evaluated in prospective clinical
trials, thus facilitating a better personalized patient
management. Second, all patients are from Zhejiang

The patients’ electronic medical data were retrieved
from the Hospital Information System (HIS). The
high-resolution CT images were retrieved from the
picture archiving and communication system of
the hospitals. The patients’ RT-PCR results were
retrieved from the electronic medical records in the
HIS. The patients with negative chest CT results or
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Patients
This study was approved by the Hangzhou Xixi
Hospital Institutional Review Board. As this is a
retrospective study, the need for written informed
consent from patients was waived. A total of 193
patients confirmed with COVID-19 or other types of
viral pneumonia were enrolled in this study. Eight
patients with negative chest CT imaging result were
excluded. A total of 108 patients with COVID-19
confirmed by RT-PCR between December 2019 and
March 2020 in the Hangzhou Xixi Hospital were
retrospectively included into this study. Another group
of 77 patients with influenza virus-induced, adenovirusinduced, syncytial virus-induced, and cytomegalovirusinduced pneumonias from Hangzhou First People’s
Hospital (19 cases) and Hangzhou Xixi Hospital (58
cases) were used as controls.
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lacking both chest CT and RT-PCR examinations were
excluded from this study. Figure 6 summarizes the
study workflow and methods.
Baseline clinical data, including patient’s age, gender,
lesion number, and five biochemical indicators
recommended in the “Handbook of COVID-19
Prevention and Treatment,’’ [29] including white blood
cell count (WBC), C-reactive protein (CRP) levels,
creatine kinase isoenzyme (CK-MB) activity, lactate
dehydrogenase (LDH) activities, and plasma D-dimer
(DD) levels, were collected by reviewing the medical
records and data of serial CT imaging, including
baseline, mid-treatment, and post-treatment CT scans,
were also recorded to monitor the disease progression.
The patients’ daily basic status, daily examination
results, and complications were also analyzed to check
how the disease progressed. Based on the RT-PCR
results for COVID-19 confirmation, the enrolled
patients were divided into two groups, i.e., the COVID19 group and the non-COVID-19 viral pneumonia
group.
CT image acquisition
All patients included underwent chest CT imaging using
a two multi-detector row CT system (GE Revolution
Evo CT, Chicago, USA; Siemens SOMATOM Emotion
16, Erlangen, Germany). The acquisition parameters
were as follows: 120/130 kV, 100/10–240 mA, 0.35- or
0.8-second rotation time, a layer spacing of 5 mm, an
acquisition layer thickness of 5 mm, high-resolution
reconstruction with a lung window layer thickness of
1.25/1.50 mm, a detector collimation of 16×0.5 mm or
64×0.625 mm, a field of view of 350×350 mm, and an
image matrix of 512×512. The CT scans before onset of
symptoms or CT scans done ≤1 week after symptom
onset were used as baseline. The baseline CTs of highly
suspected patients were used in this study. GGO and/or
consolidation are the main manifestations in the CT
images at this early stage. The other CT imaging
patterns included linear opacity, mixed type and
interstitial change patterns including septal thickening
and fine reticular opacity, and other features including
vascular thickening, crazy paving pattern, pleural
thickening, and pleural effusion.
Human diagnosis of COVID-19 using a human
supervised learning fashion
To compare the classification performance between the
COVID-19 risk scores developed and radiologists, 147
radiologists were invited to differentiate COVID-19
from the virus-induced pneumonias based on the CT
manifestations only. The diagnosis was performed using
a human supervised learning fashion.
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A total of five COVID-19 CT images and five influenza
virus-induced, adenovirus-induced, syncytial virusinduced, and cytomegalovirus-induced pneumonia
images were randomly drawn from the total patient
cohort to form a learning sample set. These learning
sample images along with the CT manifestations
described in the China Clinical Consensus on
Radiological Diagnosis on COVID-19 [29] were used to
train 130 radiologists in China with thoracic CT
diagnosis experiences ranging from assistant attending
radiologists or associate attending radiologists to
attending radiologists using a human supervised learning
fashion. The radiologists were then given the remaining
176 CT images without the clinical and follow-up
information provided. Based on the CT manifestations
they learned from the 10 image samples provided, the
radiologists diagnosed whether these 176 CT images
were COVID-19 or influenza virus-/adenovirus-/
syncytial virus-/cytomegalovirus-induced pneumonias.
The accuracy and the average time for diagnosis per CT
image were used for statistical analysis. To rule out the
random diagnosis, two equal CT images were mixed
within the 176 CT images, and if the radiologist’s
answers were not consistent for these two images, his or
her answers were excluded from the statistical analysis.
A total of 130 radiologists’ diagnoses were eligible for
statistical analysis (40 radiologists from Hubei Province,
the epicenter of the COVIA-19 outbreak in China, and 90
radiologists from outside of Hubei Province).
Radiomic feature extraction
Before extracting all chest CT radiomic features, 3D
adaptive histogram equalization enhancement (AHEE3D) and edge preserve smooth 3D (EPS-3D) methods
were used to remove random noise in the images. The
lesions of pneumonias on CT images were reviewed and
manually delineated by two experienced attending
radiologists who were blind to the clinical and followup information. The final contour for each lesion was
agreed upon by both radiologists. The patient-based and
lesion-based analyses were performed. The lesion
region of interest (ROI) was segmented on the CT
image as the only input for radiomics analysis of
pneumonia.
A total of 1766 radiomic features were extracted from
each ROI delineated using the image biomarker explorer
(IBEX) public platform developed by the University of
Texas MD Anderson Cancer Center for feature extraction
and classification of radiomic features [30, 31]. The
radiomic features extracted include seven categories:
shape, intensity direct, intensity histogram, gray-level cooccurrence matrix (2.5D and 3D), neighbor intensity
difference (2.5D and 3D), gray-level run length matrix
(2.5D), and intensity histogram Gauss fit.
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Figure 6. The workflow for the development and validation of COVID-19 risk scores.
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It is believed that some of the radiomic features are
sensitive to each step of the data processing procedure,
including
image
acquisition
settings,
image
reconstruction algorithm, and the digital image
preprocessing procedure, so that the repeatability and
reproducibility of the extraction of these radiomic
features are easily compromised [32]. To account for
the potential impact of the accuracy of radiomic feature
extraction, the radiomic feature extraction procedure
was repeated twice and Lin’s concordance correlation
coefficient (CCC) tests were performed to assess the
feature reproducibility in repeated feature extraction
[33, 34]. Only the 1237 radiomic features showing high
CCC values (CCC > 0.99) were used. With 1237
radiomic features selected, 510 features with null value
were eliminated and the remaining 727 radiomic
features plus 9 clinical variables (lesion number, age,
gender, WBC, LC, CRP level, LDH activity, CK-MB
activity, and plasma DD level) were used for further
analysis.
Patient-based risk scores
Of the patient data, 25% was randomly selected as an
independent validation set (n = 46) and the remaining
75% of the patient data were used for the training set
(n = 139). The ratio of COVID-19 to non-COVID-19
patients was about 1.41:1 in the training and validation
sets (in the training set, COVID-19:non-COVID-19 =
81:58 patients; in the validation set, COVID-19:nonCOVID-19 = 27:19 patients).
For our patient-based analysis, the same features
extracted from multiple lesions within one single patient
were combined using a weighted power mean method
[35]. Briefly, all lesions of the patient were delineated
and the radiomic features were extracted. A weighting
calculation was performed to combine the same feature
from different lesions within the same patient as
described in the following equations (Equation 6):

n

F ( j) =

V

Vi

i =1

 f j (i )

T

n

VT =

(6)

V ,
i

i =1

where F(j) represents the value of the j-th radiomic
feature of the patient, i represents the i-th lesion of the
patient, V(i) represents the volume of the i-th lesion, n
represents the number of lung lesions in the patient, VT
represents the total volume of all lesions in the patient,
and fj(i) represents the value of feature j in the i-th
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lesion. The weight assigned was based on the volume of
the lesion. The larger the lesion volume, the greater the
weight value of the features extracted from that lesion.
Thus the contribution of the features extracted from this
lesion to the patient’s radiomic feature was also greater.
Owing to the imbalanced sample distribution between
COVID-19 and non-COVID-19 patients (the number of
non-COVID-19 patient is lower than the number of
COVID-19 patients), synthetic minority over-sampling
technology [36–40] was used to generate synthetic nonCOVID-19 patient samples in the training set so that a
synthetically class-balanced training set could be
achieved prior to training the models in this study.
Briefly, for each minority sample “a” in the nonCOVID-19 patient group, the synthesis strategy was
applied to randomly select a minority sample “b” from
its nearest neighbors. And then one point was randomly
selected as the newly synthesized non-COVID-19
patient sample on the line between “a” and “b,” so that
the ratio of COVID-19 and non-COVID-19 patients in
the training set was close to 1:1.
Three signatures, including a risk score using radiomic
features only, a risk score using clinical factors only, and
a risk score combining radiomic features and clinical
variables, were built in this study (Figure 7). For the
construction of the risk score using radiomic features
only and the risk score combining radiomic features and
clinical variables, principal component analysis (PCA),
the Mann–Whitney U test, and least absolute shrinkage
and selection operator (LASSO) regression with a four
fold cross-validation method and a 100 times iterative
selection process were successively applied to eliminate
redundant features and irrelevant variables to establish
the COVID-19 risk scores. A multivariate logistic
regression method was used to build these two risk
scores. For the construction of the risk score using
clinical factors only, because the number of clinical
factors is much lower than the number of radiomic
features, a multivariate logistic regression method
was directly applied to build the clinical signature. The
model performance of the three risk scores was
evaluated in the training and independent validation sets.
For the construction of the risk score using radiomic
features only and the risk score combining radiomic
features and clinical factors, PCA was used to reduce
the feature dimensionality and select the radiomic
features and radiomic features plus clinical variables
that accounted for 90% of the significant feature subset
variability to increase the discriminative ability. After
PCA analysis, the feature dimensionality was reduced
from 727 radiomic features to 32 features for the risk
score using radiomic features only (Supplementary
Table 1), and from 727 radiomic features plus 9 clinical
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Figure 7. The workflow of the construction of the patient-based risk scores using radiomic features only, the risk score using
clinical factors only, and the risk score combining radiomic features and clinical variables using a multivariate logistic
regression method and a random forest model.
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variables to 26 features for the risk score combining
radiomic features and clinical factors (20 radiomic
features plus 6 clinical variables including lesion
number, gender, WBC, CRP level, LDH activity, CKMB activity, and plasma DD level) (Supplementary
Table 2).
The Mann–Whitney U test was used to further explore
the potential association of the features/variables
selected from PCA with COVID-19 and further reduce
the feature dimensions. For the risk score using radiomic
features only (Supplementary Table 3), the feature
dimensions were reduced from 32 to 20 radiomic
features. For the risk score combining radiomic features
and clinical factors, the feature dimensions were reduced
from 26 to 17 features (11 radiomic features plus 6
clinical variables including lesion number, gender,
WBC, CRP level, LDH activity, and CK-MB activity)
(Supplementary Table 4).
To select the most suitable features for classification of
COVID-19, LASSO regression with a four fold crossvalidation method and a 100 times iterative selection
process was used to continually choose non-redundant
and the most robust radiomic features and radiomic
features and clinical variables, respectively [41, 42]. The
coefficient of each variable was controlled by the
parameter λ in the LASSO method and only the features
with non-zero coefficients were selected. The
misclassification error was calculated to minimize the
binary classification error and maintain a balance of
optimal classification performance and the optimal
number of radiomic features needed for binary
classification (COVID-19 vs. non-COVID-19).
As such, for the risk score using radiomic features only,
only those 16 features with non-zero coefficients were
selected via the LASSO process (Supplementary Table
5 and Supplementary Figure 1). For the risk score
combining radiomic features and clinical variables, only
those five features with non-zero coefficients were
selected via the LASSO process (two radiomic features,
GLRLM_LRLGE_(25,90) and ID_Global_Max, plus
three clinical variables, lesion number, LDH activity,
and CK-MB activity) (Supplementary Table 6 and
Supplementary Figure 2).
After the feature dimensionality was reduced, a
multivariable logistic regression analysis was employed
and only the features with P < 0.001 in this process were
selected to build the COVID-19 risk scores. For the risk
score using radiomic features only, two radiomic
features, GLRLM_LRLGE_(25,90) and ID_Global_
Max, were finally preserved (Supplementary Table 7).
For the risk score combining radiomic features and
clinical variables, seven features were further reduced to
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five features (two radiomic features, GLRLM_LRLGE_
(25,90) and ID_Global_Max, plus three clinical
variables, lesion number, LDH activity, and CK-MB
activity) (Supplementary Table 8). The COVID-19 risk
scores using radiomic features only and using radiomics
and clinical variables were built as the final classifiers by
summing these features multiplied with their respective
coefficients.
The COVID-19 risk scores developed were also
represented by nomograms. The threshold of using the
risk score using radiomic features only to classify
COVID-19 is 0.2. The threshold of using the risk score
with combined radiomic and clinical variables to
classify COVID-19 is 0.5. DCA was applied to evaluate
the clinical decision utility of the COVID-19 risk scores
developed [34, 35]. The definition of net benefit in the
DCA is described in Supplementary Appendix 1.
For the risk score using clinical factors only, the
multivariable logistic regression analysis was directly
employed and only the variables with P < 0.001 in this
process were selected to build the COVID-19 risk score,
including lesion number, LDH activity, and CK-MB
activity (Supplementary Table 9). The COVID-19 risk
score using clinical factors only was also represented by
a nomogram. The threshold using a nomogram to
classify COVID-19 is 0.5.
Patient-based random forest models
As a comparison to the patient-based COVID-19 risk
scores developed, three random forest classifiers using
radiomic features only, clinical factors only, and a
combination of radiomic features and clinical factors
were also constructed using grid search with fourfold
cross-validation with the following parameters: the
number of trees in the forest (ntree) = 500 and the
maximum depth of the tree (mtry) = 3.
Lesion-wise COVID-19 risk score with radiomic
features only
A lesion-based COVID-19 risk score using radiomic
features alone was also built so that potentially different
infectious lesions could be characterized individually.
In total, 772 COVID-19 lesions were extracted from
COVID-19 patients and 83 non-COVID-19 lesions were
extracted from related viral pneumonia patients in this
study.
The feature dimensionality reduction was conducted to
select the optimal radiomic features. Briefly, a total of
1766 radiomic features were extracted from each lesion
individually. After eliminating the radiomic features
with null values and employing PCA, 32 radiomic
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features were used for the Mann–Whitney U test
(Supplementary Table 10). The Mann–Whitney U test
further reduced the feature dimensions from 32 to 20
features (Supplementary Table 11). The LASSO
regression further selected the 10 non-redundant and
most robust radiomic features (Supplementary Table 12
and Supplementary Figure 3).
After the feature dimensionality was reduced, the
multivariable logistic regression analysis was employed
to choose the radiomic features with P < 0.001 to build
the lesion-based COVID-19 risk score with radiomic
features alone so that 10 features were further reduced
to 3 features: GLCM_Correlation_(25,0,1), ID_Local_
Range_Std, and GOH_Percentile_(15) (Supplementary
Table 13). The lesion-based COVID-19 risk score based
on three features only was also represented by a
nomogram. The threshold of using the risk score to
classify COVID-19 is 0.5. DCA was also employed to
evaluate the clinical decision utility of the nomogram
developed [43, 44].
Lesion-based weighted support vector machine
analysis
As a comparison to the lesion-based COVID-19 risk
score using radiomic features alone, a lesion-based
WSVM analysis was also conducted using the 10
radiomic features (Supplementary Table 12) selected by
the LASSO. The data distribution between the COVID19 and non-COVID-19 lesions (approximately 9.3:1)
was extremely imbalanced. To ensure the models with
predictive power were equally balanced between
COVID-19 and non-COVID-19, a previously described
strategy was used to adjust the distribution imbalance
between COVID-19 and non-COVID-19 lesions and
construct the WSVM [45].
Briefly, the strategy is to separate the major class (i.e.,
the COVID-19 lesion group in this study) into small
subset groups size-comparable to the minor class (i.e.,
the non-COVID viral pneumonia lesion group in this
study) to achieve a balanced distribution between the
major class and the minor class; the COVID-19 lesion
groups was randomly decomposed into nine partitions,
and all the non-COVID-19 lesions were combined with
each partition of COVID-19 lesions to form an
individual subset so that the ratio of the COVID-19 and
non-COVID-19 lesions was nearly 1:1 in each
individual subset. In each individual subset, the total
lesions were randomly separated into the training set
(70%) and the validation set (30%).
The support vector machine (SVM) was trained
independently with 10 radiomic features selected by the
LASSO process within the training set of each subset.
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The weight for the SVM was determined via the recall
value of the prediction using the validation set to reduce
the false negative rate. In each individual subset, the
SVM generated was validated with the validation set of
each subset (i.e., the balanced data of each subset) as
well as the validation set of the entire data to evaluate
the classification performances (Supplementary Table 14
and Supplementary Figure 4).
Finally, all constituent SVMs were combined by
summing constituent SVMs multiplied by weights
determined, divided by the sum of the weights. The
classical (metric) multidimensional scaling matrix
(CMDScale) was used to demonstrate the correlation of
features and COVID-19 for each constituent SVM.
Performance evaluation and statistical analysis
The AUC between the risk scores and the random forest
models and the WSVM model was compared using the
Delong test. Six metrics, including precision, recall
(sensitivity), specificity, F1, accuracy, and AUC, were
calculated from the receiver operating characteristic
(ROC) curve with the model output.
The classification performances of COVID-19 by the
developed risk scores were assessed by ROC analysis.
For numeric variables, mean and standard deviation
were calculated and the differences between COVID-19
and non-COVID-19 patient groups were compared
using rank-sum tests. A two-tailed P value less than
0.05 was regarded as statistically significant.
Data sharing
The datasets analyzed in this study will be available
from the corresponding author (Xiadong Li, email:
lixiadong2019@outlook.com) at the time of publication.
Per institutional policy, the datasets are designated
limited access. Upon receiving access, the investigator
may only use them for the purposes outlined in the
request to the data provider, and redistribution of the
data is prohibited.
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SUPPLEMENTARY MATERIALS
Supplementary Appendix 1
Definition of net benefit in the decision curve
analysis
The net benefit [1, 2] was defined by the following
equation:
Net Benefit = TPR  ω −

Pt
 FPR  (1 − ω)
1 − Pt

(1)

Pt is the “threshold possibility” to stratify the patients
into high-risk COVID-19 or low-risk non-COIVD-19
groups. Patients with a probability of having COVID-19
higher than Pt are high-risk patients. TPR is the true
positive rate, defined as the proportion of high-risk
patients in the patients having COVID-19. FPR is the
false positive rate, defined as the proportion of high-risk
patients in the patients having non-COVID-19. ω is the
prevalence of having COVID-19, calculated by dividing
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the total patients number by the number of patients with
COVID-19. In this study, the treat-all scheme assumes
that all the patients were COVID-19; the treat-none
scheme assumes that all the patients were non-COVID19. In the condition of “treat none”, no patient is
classified as high risk, both the TPR and FPR are zero,
so the Net Benefit is zero. In the condition of “treat all”,
all patients are classified as high risk COVID-19
(TPR=FPR=1), so the Net Benefit is calculated as

Net BenefitTreat Everyone = ω −
1− ω
=
+1
Pt − 1

Pt
 (1 − ω)
1 − Pt

(2)

, which is a monotonically decreasing dash-line curve in
the figure.
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Supplementary Appendix 2
The procedure of using the nomogram of the risk
score combining radiomic features and clinical
factors
This is the patient-based risk score integrating 2
radiomic features and 3 clinical variables. For
example, a suspicious patient was found having
the following radiomic features and clinical
factors detected/calculated: lesions numbers = 5,
GLRM_LRLGE_(25,90) = 0.3, ID_Global_Max =
2000, lactate dehydrogenase = 750 u/mg, creatine
kinase isoenzymes = 10 ug/L. The values in the Points
line in the 1st row corresponding to these radiomic
features and clinical factors are 28, 58, 17, 32, 48. As
such, the total point adding all the values in the Points
line is 183 in the Total points line in the 7th row. So,
the patient's risk of COVID-19 can be calculated from
this nomogram with a risk score close to 0.95.
Alternatively, all radiomic features and clinical
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factors detected/calculated can be plugged into the
risk score equation to get the score value:

The patient − based risk score combining radiomics
and clinical features
= −114.053 + 9.529  lesion number + 122.045
 GLRLM_LRLGE_(25,90) + 0.0196
 ID_Global_Max + 0.334
 lactate dehydrogenase − 7.593

(3)

 creatine kinaseisoenzymes
= −114.053 + 9.529  5 + 122.045
 0.3 + 0.0196  2000 + 0.334  750
− 7.593  10 = 183.9755
The score of 183.9755 is corresponding to 0.95 on the
COVID-19 Risk line in the 8th row of the nomogram.
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Supplementary Appendix 3
The influence of bias induced in the boundary and
volume contoured in the manual delineating process
on the radiomics values calculated
To further verify the repeatability of two features
GLRLM_LRLGE_ (25, 90) and ID_Global_Max
selected in the construction of patient-based risk scores
in this study, a verification study was conducted. A
CT data set from one COVID-19 patient was used
for delineation by five different radiologists and the
differences of volumes and surface areas caused by
different delineations were calculated (Supplementary
Figure 6). The 5 volumes-of-interest (VOIs) delineated
were also used for the GLRLM_LRLGE_ (25, 90) and
ID_Global_Max feature extraction and calculation.
Three different tools (2 open sources ((image biomarker
explorer (IBEX) [3] and Pyradiomics [4]) and 1 inhouse Matlab codes) were used to extract and calculate
the radiomic feature values of the GLRLM_LRLGE_
(25, 90) and ID_Global_Max. The patient-based
COVID-19 risk score using radiomic features only was
calculated using the radiomic features extracted from 5
VOIs contoured according to the formula developed in
this study (Equation 5). The results are shown in
Supplementary Table 15 as follows.

Furthermore, the same verification study was also
repeated on three radiomic features identified in the
lesion based analysis and the results were shown in
Supplementary Table 16. Similarly, the VOI delineation
biases induced by different radiologists had a relatively
small impact on the radiomic feature values of
GOH_Percentile_(15), GLCM_Correlation_(25,0,1) and
ID_Local_range_std as well as the COVID-19 risk score
values calculated. In addition, the feature extractions on
the VOIs contoured using different tools had not
significantly affected the calculation of COVID-19
risk score.
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The patient-based risk score using radiomic features only
= −3.785 + 19.563  GLRLM_LRLGE_(25,90) + 0.002
 ID_Global_Max

As shown in Supplementary Table 15, the VOI
delineation biases induced by different radiologists had
a relatively small impact on the radiomic feature values
of GLRLM_LRLGE_ (25, 90) and ID_Global_Max as
well as the COVID-19 risk score values calculated. In
addition, the feature extractions on the VOIs contoured
using different tools had not significantly affected the
calculation of COVID-19 risk score, which could be
considered to be a good repeatability.
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Supplementary Figures

Supplementary Figure 1. The LASSO process to select the radiomic features for the construction of the patient-based risk
score using radiomic features only. (A) The radiomic features selection procedure using LASSO regression method. To determine the
best features combination for building the risk score, the control parameter λ value in the LASSO model was selected via 4-fold crossvalidation with minimum criteria. The x-axis is the value of log (λ) and the y-axis is the binominal deviance in the 4-fold cross validation
method 100 times. The upper x-axis is the number of non-zero-coefficient features with a given λ. The red curve indicated the average
binominal deviance value with the vertical bars showing the upper and lower boundaries. The left vertical dotted line defined the λ with the
least binomial deviance. The right vertical dotted line indicates the largest value of λ such that the binominal deviance is within one standard
error of the minimum binominal deviance. (B) The LASSO coefficient profiles of the radiomic features. The figure shows the feature
coefficient change with the tuning of λ value. The dotted line was plotted at the λ value determined in (A) resulting 16 non-zero-coefficient
radiomic features.
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Supplementary Figure 2. The LASSO process to select the radiomics features and clinical variables for the construction of the
patient-based risk score combining radiomic features and clinical variables. (A) The radiomic features and clinical variables
selection procedure using LASSO regression method. To determine the best features combination for building the risk score, the control
parameter λ value in the LASSO model was selected via 4-fold cross-validation with minimum criteria. The x-axis is the value of log (λ) and the
y-axis is the binominal deviance in the 4-fold cross validation method 100 times. The upper x-axis is the number of non-zero-coefficient
features with a given λ. The red curve indicated the average binominal deviance value with the vertical bars showing the upper and lower
boundaries. The left vertical dotted line defined the λ with the least binomial deviance. The right vertical dotted line indicates the largest
value of λ such that the binominal deviance is within one standard error of the minimum binominal deviance. (B) The LASSO coefficient
profiles of the 17 radiomic features and clinical variables. The figure shows the feature coefficient change with the tuning of λ value. The
dotted line was plotted at the λ value determined in (A) resulting 5 non-zero-coefficient radiomic features and clinical variables.
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Supplementary Figure 3. The LASSO process to select the radiomic features for the construction of lesion-based risk score
using radiomic features alone. (A) The radiomic features selection procedure using LASSO regression method. To determine the best
features combination for building the risk score, the control parameter λ value in the LASSO model was selected via 4-fold cross-validation
with minimum criteria. The x-axis is the value of log (λ) and the y-axis is the binominal deviance in the 4-fold cross validation method 100
times. The upper x-axis is the number of non-zero-coefficient features with a given λ. The red curve indicated the average binominal deviance
value with the vertical bars showing the upper and lower boundaries. The left vertical dotted line defined the λ with the least binomial
deviance. The right vertical dotted line indicates the largest value of λ such that the binominal deviance is within one standard error of the
minimum binominal deviance. (B) The LASSO coefficient profiles of the radiomic features. The figure shows the feature coefficient change
with the tuning of λ value. The dotted line was plotted at the λ value determined in (A) resulting the 10 non-zero-coefficient radiomic
features.
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Supplementary Figure 4. The correlation of radiomics features and COVID-19 for each constituent SVM. (A, C, E, G, I, K, M, O,
Q): The heat maps of correlation of radiomics features and COVID-19 for 9 individual constituent SVM. (B, D, F, H, J, L, N, P, R): The classical
(metric) multidimensional scaling matrix to demonstrate the discriminative abilities of the individual constituent SVM to classify COVID-19
and non-COVID-19 using 9 constituent SVM individually. Abbreviations: SVM, support vector machine.

Supplementary Figure 5. The geographic distribution of 130 radiologists from 10 provinces in China including Hubei
province, the epicenter of COVID-19 outbreak in China.

www.aging-us.com

9214

AGING

Supplementary Figure 6. Segmentations from 5 radiologists to delineate the volumes of interest in the same COVID-19
patient.
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Supplementary Tables
Please browse Full Text version to see the data of Supplementary Tables 15, 16.

Supplementary Table 1. The 32 radiomic features selected by principal component analysis (PCA) for dimensionality
reduction to construct the patient-based risk score using radiomic features only.
Radiomic features
Shape_Convex
Shape_Convex_Hull_Volume
GOH_Percentile_(15)
GOH_Percentile_(50)
GLCM_Cluster_Prominence_(25,333,4)
GLCM_Cluster_Prominence_(25,315,4)
GLCM_Cluster_Shade_(25,333,4)
GLCM_Cluster_Shade_(25,315,4)
GLCM_Cluster_Shade_(25,315,7)
GLCM_Contrast_(25,0,10)
GLCM_Contrast_(25,90,7)
GLCM_Contrast_(25,270,4)
GLCM_Correlation_(25,0,1)
GLCM_Correlation_(25,0,4)
GLCM_Correlation_(25,90,4)
GLCM_Difference_Entropy_(25,333,1)
GLCM_Dissimilarity_(25,333,7)
GLCM_Energy_(25,45,4)
GLCM_Energy_(25,45,7)
GLCM_Energy_(25,135,4)
GLCM_Information_Measure_Corr1_(25,0,1)
GLCM_Information_Measure_Corr2_(25,315,1)
GLCM_Inverse_Diff_Moment_Norm_(25,135,4)
GLCM_Inverse_Diff_Moment_Norm_(25,225,4)
GLCM_Inverse_Diff_Moment_Norm_(25,270,7)
GLCM_Inverse_Variance_(25,225,4)
GLCM_Inverse_Variance_(25,315,4)
GLCM_Max_Probability_(25,180,1)
GLCM_Sum_Entropy_(25,180,7)
ID_Kurtosis
ID_Local_Range_Std
IH_Percentile_Area_(30)

Coefficients
0.913
0.926
0.933
0.979
0.901
0.972
0.754
0.829
0.936
0.689
0.757
0.837
0.306
0.954
0.661
0.396
0.925
0.931
0.486
0.654
0.671
0.432
0.779
0.828
0.669
0.534
0.289
0.275
0.439
0.354
0.119
0.387

Cumulative%
37.116
54.347
66.221
75.455
80.369
84.221
86.194
87.825
89.214
90.605
91.711
92.582
93.401
94.124
94.813
95.446
95.967
96.548
96.985
97.386
97.782
98.097
98.395
98.672
98.884
99.093
99.287
99.454
99.602
99.74
99.879
100

Explainable variance ratio%
37.116
17.231
11.874
9.234
4.914
3.852
1.973
1.631
1.389
1.391
1.106
0.871
0.819
0.723
0.689
0.633
0.521
0.581
0.437
0.401
0.396
0.315
0.298
0.277
0.212
0.209
0.194
0.167
0.148
0.138
0.139
0.121

The values in the brackets represent the parameters used to calculate that particular radiomic feature.
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Supplementary Table 2. The 20 radiomic features plus 6 clinical variables selected by principal component analysis
(PCA) for dimensionality reduction to construct the patient-based risk score combining radiomic features and clinical
variables.
Radiomic features and clinical variables
Lesion number
Lactate dehydrogenase
C-reactive protein
Gender
White blood cell
D-dimers
Shape_Compactness_(2)
Shape_Convex_Hull_Volume
Shape_Orientation
Shape_Roundness
GOH_Percentile_Area_(15)
GOH_Percentile_Area_(70)
GOH_Range
GLCM_Cluster_Prominence_(25,333,4)
GLCM_Cluster_Shade_(25,333,4)
GLCM_Correlation_(25,333,1)
GLCM_Correlation_(25180,7)
GLCM_Difference_Entropy_(25,333,1)
GLCM_Information_Measure_Corr_(2,25,333,7)
GLCM_Max_Probability_(25,333,1)
GLCM_Max_Probability_(250,7)
GLRLM_Long_Run_Low_Gray_Level_Empha_(2590)
ID_Global_Max
ID_Local_Entropy_Std
ID_Percentile_(30)
IH_Percentile_(30)

Coefficients
0.866
0.829
0.756
0.932
0.689
0.832
0.911
0.874
0.829
0.543
0.886
0.851
0.944
0.756
0.813
0.925
0.866
0.862
0.642
0.473
0.455
0.856
0.865
0.674
0.498
0.563

Cumulative%
33.623
44.588
53.795
61.926
69.029
75.902
81.423
85.786
88.938
91.042
92.476
93.494
94.497
95.499
96.400
97.143
97.620
98.081
98.533
98.845
99.078
99.289
99.498
99.699
99.863
100.000

Explainable variance ratio%
33.623
10.965
9.207
8.131
7.103
6.873
5.521
4.363
3.152
2.104
1.434
1.018
1.003
1.002
0.901
0.743
0.477
0.461
0.452
0.312
0.233
0.211
0.209
0.201
0.164
0.137

The values in the brackets represent the parameters used to calculate that particular radiomic feature.
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Supplementary Table 3. The 20 radiomic features selected by the Mann-Whitney U test for dimensionality reduction
to construct the patient-based risk score using radiomic features only.
Radiomic feature
Shape_Convex_Hull_Volume
GOH_Percentile_(15)
GOH_Percentile_(50)
GLCM_Cluster_Prominence_(25,333,4)
GLCM_Cluster_Prominence_(25,315,4)
GLCM_Cluster_Shade_(25,315,7)
GLCM_Correlation_(25,0,1)
GLCM_Contrast_(25,0,1)
GLCM_Contrast_(25,270,4)
GLCM_Difference_Entropy_(25,333,1)
GLCM_Dissimilarity_(25,333,7)
GLCM_Energy_(25,135,4)
GLCM_Energy_(25,225,4)
GLCM_Information_Measure_Corr1_(25,0,1)
GLCM_ Information_Measure_Corr2_(25,315,1)
GLCM_Inverse_Diff_Moment_Norm_(25,90,7)
GLCM_Inverse_Diff_Moment_Norm_(25,270,7)
GLCM_Sum_Entropy_(25,180,7)
ID_Kurtosis
ID_Local_Range_Std

AUC
0.704
0.890
0.688
0.544
0.509
0.438
0.853
0.972
0.781
0.940
0.532
0.557
0.532
0.623
0.567
0.540
0.677
0.684
0.734
0.976

95% CI
0.664-0.808
0.828-0.921
0.618-0.778
0.464-0.632
0.458-0.613
0.367-0.557
0.803-0.903
0.912-0.998
0.713-0.872
0.876-0.984
0.429-0.613
0.465-0.604
0.487-0.612
0.539-0.719
0.509-0.633
0.512-0.634
0.621-0.759
0.589-0.704
0.633-0.811
0.909-0.994

P
0.000
0.000
0.321
0.467
0.218
0.000
0.000
0.000
0.000
0.000
0.311
0.231
0.367
0.000
0.000
0.000
0.000
0.000
0.000
0.216

The values in the brackets represent the parameters used to calculate that particular radiomic feature.

Supplementary Table 4. The 11 radiomic features and 6 clinical variables selected by the Mann-Whitney U test for
dimensionality reduction to construct COVID-19 risk score using radiomic features and clinical variables.
Radiomic features and clinical variables
Lesion number
Gender
White blood cell
C-reactive protein
Lactate dehydrogenase
Creatine kinase isoenzyme
Shape_Compactness_(2)
GOH_Range
GLCM_Cluster_Prominence_(25,333,4)
GLCM_Correlation_(25,333,1)
GLCM_Difference_Entropy_(25,333,1)
GLCM_MaxProbability_(250,7)
GLRLM_LRLGE_(25,90)
ID_GlobalMax
ID_Percentile_(30)
IH_Percentile_(30)
IH_Percentile_Area

AUC
0.956
0.463
0.394
0.674
0.887
0.069
0.365
0.678
0.604
0.287
0.724
0.365
0.767
0.791
0.368
0.303
0.387

95% CI
0.909-0.994
0.274-0.554
0.369-0.551
0.593-0.751
0.804-0.915
0.036-0.081
0.278-0.434
0.576-0.717
0.512-0.723
0.209-0.353
0.667-0.771
0.312-0.423
0.676-0.812
0.695-0.853
0.311-0.467
0.286-0.431
0.271-0.463

P Value
0.000
0.673
0.421
0.000
0.000
0.000
0.003
0.000
0.004
0.000
0.000
0.009
0.000
0.000
0.001
0.003
0.000

The values in the brackets represent the parameters used to calculate that particular radiomic feature.
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Supplementary Table 5. The 16 radiomic feature selected by the LASSO for
dimensionality reduction to construct the patient-based risk score using
radiomic features only.
Radiomic feature
Intercept
Shape_Convex_Hull_Volume
GOH_Percentile_(15)
GOH_Percentile_(50)
GLCM_AutoCorrelation(250,1)
GLCM_ClusterProminence(25,315,4)
GLCM_ClusterShade(25,315,4)
GLCM_Correlation_(25,0,1)
GLCM_Difference_Entropy_(25,333,1)
GLCM_Dissimilarity_(25,333,7)
GLCM_Information_Measure_Corr1_(25,0,1)
GLCM_Inverse_Diff_Moment_Norm_(25,90,7)
GLCM_Inverse_Diff_Moment_Norm_(25,270,7)
GLCM_InverseDiffMomentNorm(25,270,4)
GLCM25180_7SumEntropy
ID_Kurtosis
ID_Local_Range_Std

Lambda
1.04E-02
2.07E-01
-8.58E-02
-4.07E-05
-3.58E-06
-2.02E-05
4.63E-02
4.04E-01
-4.26E-01
6.11E+02
1.49E+01
7.88E+01
7.91E-13
3.54E+00
-1.83E-01
3.45E-02
1.04E-02

The values in the brackets represent the parameters used to calculate that particular
radiomic feature.

Supplementary Table 6. The 2 radiomic features and 3 clinical
variables selected by the LASSO for dimensionality reduction to
construct COVID-19 risk score using radiomic features and clinical
variables.
Radiomic features and clinical variables
Intercept
Lesion number
Lactate dehydrogenase
Creatine kinase isoenzyme
GLRLM_LRLGE_(25,90)
ID_GlobalMax

Lambda
-1.088064e+00
3.450725e-01
4.697555e-01
3.636614e-05
5.842366e-03
-1.605967e-01

The values in the brackets represent the parameters used to calculate that
particular radiomic feature.

Supplementary Table 7. The 2 radiomic features selected by the multivariable logistic regression to construct the
patient-based risk score using radiomic features only in the training set.
Intercept
GLRLM_LRLGE_(25, 90)
ID_Global_Max

Coef
-3.785
19.563
0.002

S.E.
27.834
175.031
0.017

Wald Z
-4.25
7.27
0.14

Pr(>|Z|)
0.898
<0.0001
0.002

AUC
..
0.813
0.853

95% CI
..
0.698-0.876
0.668-0.814

The values in the brackets represent the parameters used to calculate that particular radiomic feature.
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Supplementary Table 8. The 2 radiomic features and 3 clinical variables used by the multivariable logistic regression
to construct the COVID-19 risk score using radiomic features and clinical variables in training set.
Intercept
Lesion number
GLRLM_LRLGE_(25, 90)
ID_Global_Max
Lactate dehydrogenase
creatine kinase isoenzymes

Coef
-114.053
9.311
122.045
0.0196
0.334
-7.593

S.E.
559.175
31.132
687.176
0.045
2.063
38.179

Wald Z
-0.11
9.59
2.14
3.08
7.21
-6.23

Pr(>|Z|)
0.765
<0.0001
<0.0001
0.001
<0.0001
<0.0001

AUC
..
0.823
0.718
0.786
0.861
0.856

95% CI
..
0.793-0.906
0.624-0.845
0.667-0.822
0.779-0.916
0.793-0.991

The values in the brackets represent the parameters used to calculate that particular radiomic feature.

Supplementary Table 9. The 3 clinical variables used by the multivariable logistic regression to construct the patientbased risk score using clinical variables only in the training set.
Intercept
Lesion number
Lactate dehydrogenase
creatine kinase isoenzymes
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Coef
-15.680
2.833
0.104
-1.674

S.E.
134.812
17.532
1.337
11.294
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Wald Z
-8.13
2.31
1.19
-1.76

Pr(>|Z|)
0.898
<0.0001
<0.0001
<0.0001

AUC
..
0.812
0.857
0.844

95% CI
..
0.749-0.917
0.813-0.906
0.794-0.974
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Supplementary Table 10. The 32 radiomics features selected by principal component analysis (PCA) for
dimensionality reduction to construct lesion-based risk score using radiomic features only.
Radiomic Features
Shape_Convex
Shape_Convex_Hull_Volume
GOH_Percentile_(15)
GOH_Percentile_(50)
GLCM_Cluster_Prominence_(25,333,4)
GLCM_Cluster_Prominence_(25,315,4)
GLCM_Cluster_Shade_(25,333,4)
GLCM_Cluster_Shade_(25,315,4)
GLCM_Cluster_Shade_(25,315,7)
GLCM_Contrast_(25,0,10)
GLCM_Contrast_(25,90,7)
GLCM_Contrast_(25,270,4)
GLCM_Correlation_(25,0,1)
GLCM_Correlation_(25,0,4)
GLCM_Correlation_(25,90,4)
GLCM_Difference_Entropy_(25,333,1)
GLCM_Dissimilarity_(25,333,7)
GLCM_Energy_(25,45,4)
GLCM_Energy_(25,45,7)
GLCM_Energy_(25,135,4)
GLCM_Information_Measure_Corr1_(25,0,1)
GLCM_Information_Measure_Corr2_(25,315,1)
GLCM_Inverse_Diff_Moment_Norm_(25,135,4)
GLCM_Inverse_Diff_Moment_Norm_(25,225,4)
GLCM_Inverse_Diff_Moment_Norm_(25,270,7)
GLCM_Inverse_Variance_(25,225,4)
GLCM_Inverse_Variance_(25,315,4)
GLCM_Max_Probability_(25,180,1)
GLCM_Sum_Entropy_(25,180,7)
ID_Kurtosis
ID_Local_Range_Std
IH_Percentile_Area_(30)

Coefficients
0.919
0.977
0.867
0.867
0.912
0.858
0.673
0.895
0.920
0.494
0.695
0.817
0.208
0.850
0.659
0.569
0.819
0.878
0.401
0.418
0.618
0.412
0.468
0.781
0.676
0.476
0.178
0.211
0.365
0.313
0.121
0.371

Cumulative%
36.680
19.417
10.496
9.244
4.470
2.653
1.839
1.568
1.319
1.255
1.161
1.012
0.922
0.844
0.785
0.734
0.686
0.658
0.647
0.634
0.595
0.536
0.515
0.383
0.132
0.107
0.093
0.086
0.081
0.064
0.045
0.043

Explainable variance ratio%
36.680
56.098
66.593
75.837
80.307
82.961
84.800
86.368
87.687
88.942
90.103
91.116
92.038
92.882
93.667
94.401
95.087
95.745
96.392
97.026
97.621
98.157
98.673
99.056
99.189
99.295
99.388
99.474
99.555
99.620
99.665
99.708

The values in the brackets represent the parameters used to calculate that particular radiomic feature.
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Supplementary Table 11. The 20 radiomics features selected by the Mann-Whitney U test for dimensionality
reduction to construct the lesion-based risk score using radiomic features only.
Radiomic feature
Shape_Convex_Hull_Volume
GOH_Percentile_(15)
GOH_Percentile_(50)
GLCM_Cluster_Prominence_(25,333,4)
GLCM_Cluster_Prominence_(25,315,4)
GLCM_Cluster_Shade_(25,315,7)
GLCM_Correlation_(25,0,1)
GLCM_Contrast_(25,0,1)
GLCM_Contrast_(25,270,4)
GLCM_Difference_Entropy_(25,333,1)
GLCM_Dissimilarity_(25,333,7)
GLCM_Energy_(25,135,4)
GLCM_Energy_(25,225,4)
GLCM_Information_Measure_Corr1_(25,0,1)
GLCM_ Information_Measure_Corr2_(25,315,1)
GLCM_Inverse_Diff_Moment_Norm_(25,90,7)
GLCM_Inverse_Diff_Moment_Norm_(25,270,7)
GLCM_Sum_Entropy_(25,180,7)
ID_Kurtosis
ID_Local_Range_Std

AUC
0.715
0.837
0.669
0.499
0.480
0.441
0.809
0.884
0.713
0.837
0.493
0.511
0.474
0.570
0.529
0.542
0.712
0.732
0.714
0.932

95% CI
0.618-0.757
0.768-0.954
0.607-0.779
0.401-0.681
0.396-0.557
0.348-0.567
0.731-0.898
0.715-0.918
0.647-0.862
0.778-0.925
0.418-0.553
0.449-0.654
0.388-0.591
0.469-0.670
0.844-0.635
0.684-0.627
0.667-0.749
0.675-0.138
0.677-0.845
0.889-0.989

P
0.000
0.000
0.172
0.305
0.172
0.000
0.001
0.000
0.003
0.000
0.551
0.106
0.493
0.001
0.000
0.000
0.001
0.000
0.000
0.305

The values in the brackets represent the parameters used to calculate that particular radiomic feature.

Supplementary Table 12. The 10 radiomic features selected by the LASSO for
dimensionality reduction to construct the lesion-based risk score using radiomic
features only.
Radiomic feature
Intercept
Shape_Convex_Hull_Volume
GOH_Percentile_(15)
GLCM_Correlation_(25,0,1)
GLCM_Difference_Entropy_(25,333,1)
GLCM_Dissimilarity_(25,333,7)
GLCM_Information_Measure_Corr1_(25,0,1)
GLCM_Inverse_Diff_Moment_Norm_(25,90,7)
GLCM_Inverse_Diff_Moment_Norm_(25,270,7)
ID_Kurtosis
ID_Local_Range_Std

Lambda
-5.023
0.006
0.011
-3.858
1.916
-0.080
0.595
0.498
0.001
0.035
0.004

The values in the brackets represent the parameters used to calculate that particular
radiomic feature.
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Supplementary Table 13. The 3 radiomic features used by the multivariable logistic regression to construct the
lesion-based risk score using radiomic features only.
Intercept
GLCM_Correlation_(25, 0, 1)
ID_Local_Range_Std
GOH_Percentile_(15)

Coefficient
-55.389
-6.769
0.033
0.136

Standard error
62.895
5.811
0.002
0.052

Wald Z
-0.976
-5.023
3112
4.153

Pr(>|Z|)
0.413
<0.0001
<0.0001
0.002

AUC
0.718
0.753
0.798

95% CI
0.665-0.874
0.633-0.819
0.771-0.804

Supplementary Table 14. The diagnostic performance of individual 9 constituent SVMs.
9 Individual constituent SVM
SUB-SVM1
SUB-SVM2
SUB-SVM3
SUB-SVM4
SUB-SVM5
SUB-SVM6
SUB-SVM7
SUB-SVM8
SUB-SVM9
SUB-SVM-average
SVM
Model-G1
Model-G2
Model-G3
Model-G4
Model-G5
Model-G6
Model-G7
Model-G8
Model-G9
Model-G-average
WSVM

Validation dataset
G1
G2
G3

Precision
1.000
0.952
1.000

Recall
0.846
1.000
0.833

F1
0.917
0.976
0.909

AUC
0.909
0.963
0.9

95% CI P value
0.895-0.923
0.934-0.978
0.892-0.912

G4
G5
G6
G7
G8
G9
AVERAGE
TOTAL
TOTAL
TOTAL
TOTAL
TOTAL
TOTAL
TOTAL
TOTAL
TOTAL
TOTAL
AVERAGE
TOTAL

1.000
1.000
1.000
1.000
1.000
1.000
0.995
0.962
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
0.999

0.871
0.839
0.867
0.893
0.906
0.879
0.882
0.979
0.862
0.877
0.867
0.868
0.872
0.873
0.873
0.869
0.875
0.871
0.884

0.931
0.912
0.929
0.943
0.951
0.935
0.934
0.970
0.926
0.935
0.929
0.930
0.932
0.932
0.932
0.930
0.933
0.931
0.968

0.889
0.96
0.937
0.944
0.933
0.929
0.929
0.882
0.920
0.930
0.924
0.924
0.927
0.928
0.928
0.925
0.923
0.925
0.958

0.878-0.892
0.943-0.965
0.923-0.945
0.954-0.962
0.925-0.943
0.904-0.937
0.912-0.934 0.231
0.823-0.915
0.907-0.933
0.918-0.943
0.913-0.938
0.912-0.937
0.914-0.939
0.915-0.940
0.915-0.940
0.912-0.938
0.906-0.940
0.912-0.939 0.226
0.943-0.967 0.000

The COVID-19 lesion groups was randomly decomposed into 9 partitions, and all the non-COVID-19 lesions were combined
with each partition of COVID-19 lesions to form an individual subset (i.e., group1 (G1) –group9 (G9)).
P values: P = 0.231 represents that there are no significant differences between SUB-SVMi (i=1-9); P = 0.226 represents that
there are no significant differences between Model-Gi (i=1-9); P = 0.000 represents that there are significant differences
between SUB-SVM-average, Model-G-average and WSVM.
Abbreviations: WSVM, weighted support vector machine.
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Supplementary Table 15. The comparison of the variation of contours by different radiologists and its impact on the
calculation of COVID-19 risk score using radiomic feature only (patient based analysis).
Supplementary Table 16. The comparison of the variation of contours by different radiologists and its impact on the
calculation of COVID-19 risk score using radiomic feature only (lesion based analysis).
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